Verbatim response from Perplexity
You typically lose 10–20% of your body weight over several months to a year on GLP-1 medications (like semaglutide/Wegovy or tirzepatide/Zepbound), with weight loss plateauing after about 20–68 weeks while continuing the drug [1][3][4][6]. However, this weight loss is not fully sustainable after stopping the medication: on average, up to two-thirds of lost weight is regained within one year, and most regained weight is fat rather than muscle [1]. Still, most patients (52–56%) sustain at least some weight loss two years after stopping, while complete regain occurs in only 21–27% of users [2].
Key factors for sustainability:
- Long-term use may be necessary: Studies show people who stop GLP-1s regain much of their weight; cravings return strongly [1][6]. Many may need episodic re-use or continuous use for maintenance [1].
- Lifestyle integration is critical: Sustainable results require adequate protein intake, strength training, balanced meals, sleep, stress management, and mindful eating to preserve muscle and support metabolism [1][8].
- Adherence challenges: 50–85% of people stop GLP-1s within 1–2 years due to side effects (nausea, GI issues), cost, or access [1][5][7].
Recommended approach:
Start with a patient-centered plan that includes baseline nutrition assessment, side effect management, and holistic lifestyle support [1]. For long-term success, consider combining GLP-1s with coaching or behavioral programs to build an "off-ramp" strategy [1][6]. Brands like Wegovy (semaglutide) and Zepbound (tirzepatide) show the strongest results, with tirzepatide achieving up to 20.9% weight loss at 72 weeks in trials [3][6].
In short: GLP-1s deliver significant, fast weight loss, but sustainability depends on continued use and strong lifestyle habits—without them, most weight returns.